“…NEDD9 overexpression was reported in 1309 (52.9%) of the 2476 included patients. Amongst all study cohorts, 3 evaluated lung cancer,23,27,33 4 assessed gastric cancer,28,30,32,39 3 undertook urinary bladder carcinoma,31,34,36 2 illustrated pancreatic carcinoma,29,38 and single studies focused on breast cancer,25 colorectal cancer,24 hepatocellular carcinoma,26 renal carcinoma,37 melanoma,35 and ovarian cancer 8. Studies were conducted in China (11), Japan (1), Turkey (3), Croatia (1), and Egypt (2).…”